de.mpg.escidoc.pubman.appbase.FacesBean
English
 
Help Guide Disclaimer Contact us Login
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

DNA Methylation Biomarkers in Cancer: Progress Towards Clinical Implementation

MPS-Authors
http://pubman.mpdl.mpg.de/cone/persons/resource/persons44148

Bock,  Christoph
Computational Biology and Applied Algorithmics, MPI for Informatics, Max Planck Society;

Locator
There are no locators available
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Mikeska, T., Bock, C., Do, H., & Dobrovic, A. (2012). DNA Methylation Biomarkers in Cancer: Progress Towards Clinical Implementation. Expert Review of Molecular Diagnostics, 12(5), 473-487. doi:10.1586/erm.12.45.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0014-C824-4
Abstract
Altered DNA methylation is ubiquitous in human cancers and specific methylation changes are often correlated with clinical features. DNA methylation biomarkers, which use those specific methylation changes, provide a range of opportunities for early detection, diagnosis, prognosis, therapeutic stratification and post-therapeutic monitoring. Here we review current approaches to developing and applying DNA methylation biomarkers in cancer therapy. We discuss the obstacles that have so far limited the routine use of DNA methylation biomarkers in clinical settings and describe ways in which these obstacles can be overcome. Finally, we summarize the current state of clinical implementation for some of the most widely studied and well-validated DNA methylation biomarkers, including SEPT9, VIM, SHOX2, PITX2 and MGMT.